Back to Top
Brayton Purcell LLP
Call for A Free Consultation
Nationwide Service for over 30 years

Johnson & Johnson settles Risperdal suit

Johnson & Johnson's agrees to a $181 million settlment with 36 states and the District of Columbia over Risperdal, an antipsychotic drug used off label by elderly and children to help with bipolar disorders. The settlement comes after prosecuters said that Johnson and Johnson's pharmaceutical subsidiary Janssen failed to disclose all of the risks associated with the drug. Janssen stated the settlement was agreed to in order to avoid unnecessary expense and a prolonged legal process, as opposed to an admission of wrongdoing. The company has an additional settlement with the U.S. Justice Department pending. Refer to the New York Times and Philadelphia Inquirer for additional information.


Risperdal reproached.
Same saga here as Eli Lilly Zyprexa.
Johnson and Johnson is a trusted brand we associate with babies.
Risperdal,Zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use. An estimated 2.5 million children are now taking atypical antipsychotics. Over half are being given them for Attention Deficit Hyperactivity Disorder,many of these foster children.
Weight gain, increases in triglyceride levels and associated risks for (life-long) diabetes and cardiovascular disease.
Eli Lilly made $67 BILLION on Zyprexa!
*Tell the truth don't be afraid*
Daniel Haszard FMI

Leave a comment
Comment Information